799 related articles for article (PubMed ID: 19338056)
21. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.
Sonneveld MJ; Hansen BE; Piratvisuth T; Jia JD; Zeuzem S; Gane E; Liaw YF; Xie Q; Heathcote EJ; Chan HL; Janssen HL
Hepatology; 2013 Sep; 58(3):872-80. PubMed ID: 23553752
[TBL] [Abstract][Full Text] [Related]
22. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
[TBL] [Abstract][Full Text] [Related]
23. [A pilot study of peginterferon alfa-2a combined with short-term lamivudine therapy in HBeAg-positive chronic hepatitis B patients].
Huang ZL; Zhao ZX; Deng H; Zhang YF; Lu CR; Gao ZL
Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):419-22. PubMed ID: 20587310
[TBL] [Abstract][Full Text] [Related]
24. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B.
Rijckborst V; ter Borg MJ; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Raptopoulou-Gigi M; Ormeci N; Zondervan PE; Verhey E; van Vuuren AJ; Hansen BE; Janssen HL;
Am J Gastroenterol; 2010 Aug; 105(8):1762-9. PubMed ID: 20461068
[TBL] [Abstract][Full Text] [Related]
25. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.
Fried MW; Piratvisuth T; Lau GK; Marcellin P; Chow WC; Cooksley G; Luo KX; Paik SW; Liaw YF; Button P; Popescu M
Hepatology; 2008 Feb; 47(2):428-34. PubMed ID: 18220290
[TBL] [Abstract][Full Text] [Related]
26. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
Gheorghiţa VI; Caruntu FA; Curescu M; Olaru I; Radu MN; Colţan G; Streinu-Cercel A
J Gastrointestin Liver Dis; 2013 Mar; 22(1):27-32. PubMed ID: 23539387
[TBL] [Abstract][Full Text] [Related]
27. Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B.
Chen J; Zhang DH; Xu CR; Zhu MY; Yang ZT; Gong QM; Yu DM; Zhang XX
J Clin Virol; 2015 Nov; 72():88-94. PubMed ID: 26476325
[TBL] [Abstract][Full Text] [Related]
28. Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study.
Papadopoulos VP; Chrysagis DN; Protopapas AN; Goulis IG; Dimitriadis GT; Mimidis KP
Med Sci Monit; 2009 Feb; 15(2):CR56-61. PubMed ID: 19179968
[TBL] [Abstract][Full Text] [Related]
29. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.
Buster EH; Flink HJ; Cakaloglu Y; Simon K; Trojan J; Tabak F; So TM; Feinman SV; Mach T; Akarca US; Schutten M; Tielemans W; van Vuuren AJ; Hansen BE; Janssen HL
Gastroenterology; 2008 Aug; 135(2):459-67. PubMed ID: 18585385
[TBL] [Abstract][Full Text] [Related]
30. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients.
Moucari R; Boyer N; Ripault MP; Castelnau C; Mackiewicz V; Dauvergne A; Valla D; Vidaud M; Chanoine MH; Marcellin P
J Viral Hepat; 2011 Aug; 18(8):580-6. PubMed ID: 20487260
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.
Kim BH; Lee YJ; Kim W; Yoon JH; Jung EU; Park SJ; Kim YJ; Lee HS
Scand J Gastroenterol; 2012 Sep; 47(8-9):1048-55. PubMed ID: 22726105
[TBL] [Abstract][Full Text] [Related]
32. Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study.
Charatcharoenwitthaya P; Sukeepaisarnjaroen W; Piratvisuth T; Thongsawat S; Sanpajit T; Chonprasertsuk S; Jeamsripong W; Sripariwuth E; Komolmit P; Patcharatrakul T; Boonsirichan R; Bunchorntavakul C; Tuntipanichteerakul S; Tanwandee T;
J Gastroenterol Hepatol; 2016 Nov; 31(11):1874-1881. PubMed ID: 26997582
[TBL] [Abstract][Full Text] [Related]
33. Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B.
Chen X; Chen X; Chen W; Ma X; Huang J; Chen R
J Med Virol; 2014 Oct; 86(10):1705-13. PubMed ID: 24980710
[TBL] [Abstract][Full Text] [Related]
34. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
[TBL] [Abstract][Full Text] [Related]
35. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.
Lampertico P; Viganò M; Di Costanzo GG; Sagnelli E; Fasano M; Di Marco V; Boninsegna S; Farci P; Fargion S; Giuberti T; Iannacone C; Regep L; Massetto B; Facchetti F; Colombo M;
Gut; 2013 Feb; 62(2):290-8. PubMed ID: 22859496
[TBL] [Abstract][Full Text] [Related]
36. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
37. Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B.
Keating GM
Drugs; 2009; 69(18):2633-60. PubMed ID: 19943712
[TBL] [Abstract][Full Text] [Related]
38. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.
Marcellin P; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Jin R; Gurel S; Lu ZM; Wu J; Popescu M; Hadziyannis S;
Gastroenterology; 2009 Jun; 136(7):2169-2179.e1-4. PubMed ID: 19303414
[TBL] [Abstract][Full Text] [Related]
39. [Low-levels of HBsAg quantification at 48-week in HBeAg-negative chronic hepatitis B patients are the advantageous population for HBsAg clearance].
Yan YJ; Wang XX; Cao ZH; Lu JF; Jin Y; He ZM; Geng N; Ren S; Ma LN; Chen XY
Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):813-818. PubMed ID: 30616314
[No Abstract] [Full Text] [Related]
40. HBsAg seroconversion after pegylated interferon alfa 2a rescue in a lamivudine-resistant patient with HBeAg-negative chronic hepatitis B and favourable IL28-B genotype.
Stanzione M; Stornaiuolo G; Rizzo V; Pontarelli A; Gaeta GB
Infez Med; 2016 Jun; 24(2):144-6. PubMed ID: 27367326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]